In a search for less toxic and more potent alternatives to cisplatin, organometallic complexes have shown promising activity as anti-cancer agents. [1] [2] [3] [4] There are relatively few reported studies on the anti-cancer activity of rhodium and iridium Cp* complexes. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 16 Therefore, breaking up the rhodium and iridium dihalide Cp* dimers with different bidentate ligands led to the development of complexes which show high in vitro cytotoxic activity against tumour cell lines. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Where tested, studies have reported negligible activities of the starting dimers, i.e. [Cp*MCl2]2 (M = Rh or Ir) 16 and there have been no previously reported examples of group 9 dihalide functionalised Cp* dimers demonstrating cytotoxic behaviour. We are interested in the potential of converting these inactive dimers [Cp*MCl2]2 (M = Rh or Ir) to active cytotoxic agents through modifications of the Cp* ligand. Herein, we report the synthesis of ten complexes and a discussion of five new crystal structures of the type, [Cp MCl2]2 (M = Rh or Ir). These complexes have also been evaluated for their cytotoxic activity in vitro against three tumour cell lines. Previous data has shown that the monomers were cytotoxic and therefore these dimers were tested in the hope to deliver two metal centres to the cancerous cells, potentially increasing the potency of the complex by up to 2-fold. To allow comparisons to be made between monomer and dimer, we have explored the effects of adding monodentate pyridine ligands and bidentate picolinamide ligands to both of the functionalised Cp iridium and rhodium dimers.
Complexes 1b, 1d, 2b, 2d, 3a and 3b have been previously reported for their catalytic potential. [20] [21] [22] We investigated the immobilisation of these complexes onto Wang resin for use as recyclable transfer hydrogenation catalysts. 21 In the hope to maximise the amount of metal that can reach the cancerous cells and to increase the drugs potency, the library of dimers has been tested against human colorectal adenocarcinoma (HT-29), human ovarian carcinoma (A2780) and cisplatinresistant human ovarian carcinoma (A2780cis). Due to the ability of the cyclopentadienyl hydroxyl-substituent to bind well to solid supports and with the previous evidence we have of the Cp* ligand binding to a metal centre, 23 it is possible that this alcohol could provide stability to the metal centre if the dimer breaks apart during its interaction with cells. The preparation of the dimeric complexes 2a-2d, 3a and 3b are shown in Scheme 1. The addition of monodentate pyridine and bidentate picolinamide ligands to the dimers, gave complexes 4a, 4b, 5a and 5b. These were synthesised by a reaction of 3a or 3b with the corresponding ligand, as shown in Scheme 2. All of the complexes were characterised by 1 H and 13 C{ 1 H} NMR spectroscopy, mass spectrometry and the novel complexes by elemental analysis.
Single crystals of 2a and 2c were obtained by layer diffusion of hexane into a dichloromethane solution and vapour diffusion from dichloromethane/pentane solvent system respectively. The alcohol chain in 2c showed disorder, with four of the carbons equally occupied over two positions each ( Figure S2) . The rhodium and iridium pyridine complexes, 4a and 4b, were recrystallised from vapour diffusion of dichloromethane/ diisopropylether and chloroform/pentane solvent systems respectively. Complex 4b could not be solved to a publishable quality, however, it clearly shows the connectivity of iridium to a pyridine ligand, two chloride ligands and a 5 carbon functionalised Cp ligand. The picolinamide complexes, 5a and 5b, were crystallised using slow diffusion from a methanolic solution and layer diffusion from a dichloromethane/hexane solvent system respectively.
The complexes were obtained as orange-red single crystals and solutions were performed in either monoclinic (2a, 2c, 5a), triclinic (4a), or orthorhombic (5b) space groups. Selected bond lengths (Å) are presented in Table 1 and are in the range expected for these structures. All of the angles around the metal centre show the geometry expected for pseudo octahedral complexes which is common for these -Tables S1-2, Supplementary Information). The angles between the metal and bidentate ligands are in the range 77-91°, with the remaining three coordination sites occupied by the functionalised Cp ligand and the angles observed for their centroids (Cg) to the chloride or ligands ranges between 125-134°. Molecular structures for complexes 2a, 2c, 4a, 5a and 5b are shown in Figure 1 . The cytotoxic activities of complexes 2b-2d, 3a and 3b along with [Cp*RhCl2]2, [Cp*IrCl2]2 and cisplatin, were tested against HT-29, A2780 and A2780cis cell lines. The IC50 values (M) ± Standard Deviation are presented in Table 2 . The potency of the monomeric pyridine complexes, 4a and 4b, were assessed against HT-29 cells and the picolinamide complexes, 5a and 5b, were assessed against A2780 cells. The pyridine complexes were less active than their dimeric precursors, 2b and 3a, with a 3-fold decrease in activity observed against HT-29 between 2b (30 ± 1 M) and 4b (92 ± 1 M). Against A2780, the iridium picolinamide complex, 5b (52.5 ± 0.8 M), was also less active than its starting dimer, 3a (23.2 ± 0.8 M) with a 2.2-fold decrease in activity observed. The dimeric species, except for the anomalous result of 2b against A2780cis, upon replacing a Cp* methyl group with a longer aliphatic chain alcohol substituent, an increase in cytotoxicity is observed against all cell lines. The cytoxicity improves upon increasing the functionalisation of the Cp IC50 value and is therefore more potent. These results give the indication that the chain length of the Cp could be a feature required for increased potency. Both the rhodium and iridium complex 2d or 3b are the most potent of the dimers, with values comparable to cisplatin. Complex 2d is the first example of a cytotoxic functionalised Cp rhodium complex. Previous rhodium Cp* complexes with reported cytotoxic activity have contained bidentate ligands that were designed to intercalate with DNA. 11, 18 This rhodium 14-carbon tether dimer 2d (3.9 ± 0.1 M), shows a 24-fold increase in IC50 against A2780 when compared to the unsubstituted dimer, [Cp*RhCl2]2 (95.0 ± 2.0 M). The iridium complex 3a, with a 5 carbon chain, is significantly more active than its rhodium analogue 2b, most noticeably against the cisplatin-resistant A2780cis line with an IC50 of 28.4 ± 0.6 µM compared to 127.0 ± 6.0 M Against the A2780cis line, complexes 2d (4.9 ± 0.2 M) and 3b (5.3 ± 0.1 M) have a 2-fold increase in active when compared to cisplatin (11.1 ± 0.6 M), showing these complexes potential to circumvent cisplatin-resistance in cells.
Please do not adjust margins
Please do not adjust margins The in vitro MTT assay for determining chemosensitivity is a useful indication of drugs cytotoxicity but it provides little infor of action. To gain a preliminary insight into this, the effects of the complexes on thioredoxin reductase activity were assessed. Thioredoxin reductase (Trx-R) is one of the key anti-oxidant enzymes in the cell, is commonly over expressed in tumours and can promote tumour growth and progression. 24 We have previously reported a range of iridium picolinamide complexes that inhibit Trx-R, with IC50 values in the nanomolar range. 19, 25 This prompted us to investigate whether these novel complexes 2b, 2c, 2d, 3a and 3b reported here are also able to inhibit Trx-R activity. Significantly, all the active rhodium and iridium functionalised Cp dimers were found to be potent Trx-R inhibitors with IC50 values in the nanomolar or low micromolar range (Table 3 and Figure S1 ). 4 Complexes 2b and 2c are the most potent when assessing the chemosensitivity studies, however, they are not the most potent inhibitors of Trx-R. In fact, the least chemosensitive complex 3a is the most potent Trx-R inhibitor, with an IC50 value of 217 ± 50 nM. These results show that Trx-R inhibition may contribute to the mode of action and the anti-cancer activity of some or all of our novel complexes; although it is likely that additional mechanisms may also be important and future studies will aim to explore this further.
Conclusions
We have extended our library of complexes of the type [Cp MCl2]2 where M = Rh/Ir and Cp = C5(CH3)4(CH2)nOH, and have evaulated in vitro activities against HT-29, A2780 and A2780cis cell lines. In general, the anti-cancer activity improves upon increasing the chain length between the Cp ring and the OH, with the most promising IC50 values seen for the 14-carbon length tethered dimers. The most significant result was that of the rhodium 14-carbon tether dimer 2d (3.9 ± 0.1 M), in which a 24-fold increase in IC50 was observed when compared to the unsubstituted dimer, [Cp*RhCl2]2 (95.0 ± 2.0 M). This is the first example of a cytotoxic functionalised Cp rhodium complex. The mechanism of action of organometallic complexes is generally complex but here we demonstrate that one potential mechanism involves inhibition of, thioredoxin reductase (Trx-R) activity. In a cell free assay, complexes 2b-d and 3a inhibited Trx-R activity with IC50 values in the nanomolar range. Whilst the active complexes 2b-d and 3a-b all show potent inhibitory activity against Trx-R. There was no strict correlation with the differential cytotoxicity of the complexes suggesting that additional mechanisms might also contribute to the mode of action of these complexes.
